This study looks at the effects of Pazopanib, a medicine, on nosebleeds and anemia (low red blood cells) in people with Hereditary Hemorrhagic Telangiectasia (HHT). HHT is a genetic condition causing abnormal blood vessels and frequent nosebleeds. The study will last for 24 weeks and includes a daily pill, which is either the real drug or a placebo (a pill with no medicine). After finishing this part, you might continue with the real drug for another 24 weeks. The study checks if the medicine helps reduce nosebleeds and if it's safe.

• Duration: 24-week treatment plus 12 weeks follow-up; possible extension for another 24 weeks.
• Visits: Requires regular visits and home monitoring.
• Eligibility: Must have HHT and stable condition; meet specific health criteria.

Before joining, you must not have certain health issues, like other serious bleeding sources or recent major surgeries. If you are a woman of childbearing age, you must use reliable birth control. Men also need to use protection during the study. Participants will be closely monitored for safety and effectiveness of the treatment.